Ribociclib 400mg Clinical Trials
3 recruitingDrug
Phase 12Phase 22
Showing 1–3 of 3 trials
Recruiting
Phase 1Phase 2
Ribociclib for HR-positive HER2-negative Metastatic Breast Cancer
Breast Cancer
Nagoya City University86 enrolled1 locationNCT07164976
Recruiting
Phase 1
First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tumors and in Combination With Endocrine Therapy +/- a CDK4/6 or CDK4 Inhibitor in Patients With Advanced Solid Tumors or Advanced Breast Cancer
Breast CancerMetastatic Breast CancerHER2-negative Breast Cancer+4 more
Relay Therapeutics, Inc.930 enrolled37 locationsNCT05216432
Recruiting
Phase 2
Impact of Omitting Chemo Based on Patient's Selection for ER-Positive, HER2-Negative Breast Cancer With Ribociclib and Endocrine Therapy
Yale University140 enrolled1 locationNCT06953882